Shares of Aurinia Pharmaceuticals Inc. (TSE:AUP – Get Free Report) (NASDAQ:AUPH) dropped 3.5% during mid-day trading on Monday . The stock traded as low as C$16.41 and last traded at C$16.76. Approximately 4,611,683 shares were traded during mid-day trading, an increase of 1,906% from the average daily volume of 229,895 shares. The stock had previously closed at C$17.37.
Aurinia Pharmaceuticals Price Performance
The company has a debt-to-equity ratio of 2.69, a current ratio of 11.93 and a quick ratio of 11.02. The firm has a market cap of C$2.15 billion and a PE ratio of -11.32. The stock has a fifty day simple moving average of C$16.76.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- With Risk Tolerance, One Size Does Not Fit All
- How to Master Trading Discipline: Overcome Emotional Challenges
- Consumer Staples Stocks, Explained
- Trump Tax Reforms: 7 Stocks That Could Benefit in 2025
- What Investors Need to Know About Upcoming IPOs
- 3 Stocks Near 52-Week Lows: Why They Could Be Smart Buys Today
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
